对pT1b和pT2a黑色素瘤患者前哨淋巴结活检的批判性评估:一项全国性人群研究
该全国性人群研究利用荷兰病理数据库纳入2002至2023年诊断的36606例pT1b和pT2a黑色素瘤患者,其中16042例接受了前哨淋巴结活检。pT1b和pT2a患者前哨淋巴结阳性率分别为5%和11%,肿瘤负荷>1 mm者分别占1.5%和4.1%,对应需治疗人数(NNT)分别为69和25。作者认为pT1b黑色素瘤可能不再适合行前哨淋巴结活检,pT2a应谨慎考虑。
要点
- pT1b和pT2a黑色素瘤患者前哨淋巴结阳性率分别为5%和11%。
- 前哨淋巴结肿瘤负荷>1 mm者分别占1.5%和4.1%,NNT分别为69和25。
- 作者认为pT1b黑色素瘤可能不再适合行前哨淋巴结活检,pT2a应谨慎考虑。
核心结论
- 该全国性研究显示前哨淋巴结阳性发生率低,前哨淋巴结活检后出现显著临床结局的可能性极小。
- 鉴于获得辅助免疫治疗资格的高NNT,pT1b黑色素瘤可能不再适合行前哨淋巴结活检。
- 对于pT2a黑色素瘤患者,应仔细考虑前哨淋巴结活检,权衡有限的临床获益与潜在风险。
研究设计与样本
- 全国性、基于人群的研究,使用荷兰病理数据库(Dutch Pathology Databank)数据。
- 纳入2002年至2023年间诊断为pT1b和pT2a黑色素瘤的患者。
- 共识别36606例患者,其中16042例接受了前哨淋巴结活检。
- 主要终点为肿瘤负荷>1 mm的前哨淋巴结数量。
主要发现
- pT1b黑色素瘤患者前哨淋巴结阳性率为5%,pT2a黑色素瘤患者为11%。
- 肿瘤负荷>1 mm者在pT1b中占1.5%,在pT2a中占4.1%。
- 获得辅助免疫治疗资格的NNT在pT1b为69,在pT2a为25。
关键数值与推荐
- 根据美国癌症联合委员会(AJCC)第8版分期手册,pT1b或pT2a黑色素瘤患者只有在前哨淋巴结肿瘤负荷>1 mm时才有资格接受辅助免疫治疗。
临床怎么用
- 作者认为pT1b黑色素瘤可能不再适合行前哨淋巴结活检。
- 作者认为pT2a黑色素瘤患者应仔细考虑前哨淋巴结活检,权衡有限的临床获益与潜在风险。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Sentinel lymph node biopsy (SLNB) aims to stage patients. According to the 8th edition of the American Joint Committee on Cancer(AJCC) staging manual, patients with pT1b or pT2a melanoma can be eligible for adjuvant immunotherapy, however, only if they have a sentinel node (SN) tumour burden > 1 mm. This study aims to determine the percentage of patients with pT1b or pT2a that will become eligible for adjuvant immunotherapy following SLNB. METHODS: A nationwide, population-based study was conducted using data from the Dutch Pathology Databank. Patients diagnosed with pT1b and pT2a melanoma between 2002 and 2023 were included. The primary endpoint was the number of SNs with a tumour burden > 1 mm. RESULTS: We identified 36,606 patients of who 16,042 underwent SLNB. SN positivity was 5 % for patients with pT1b melanoma, and 11 % for pT2a melanoma. A tumour burden > 1 mm was found in 1.5 % and 4.1 %, translating to a number needed to treat (NNT) of 69 for pT1b and 25 for pT2a. CONCLUSION: This nationwide study demonstrated a low incidence of positive SNs and minimal likelihood of significant clinical outcomes following SLNB. Given the high NNT to be eligible for adjuvant immunotherapy, SLNB may no longer be justified for pT1b melanoma. For patients with pT2a melanoma, SLNB should be considered carefully, balancing limited clinical benefits against potential risks.
引用
- Stassen RC, Schurink AW, van der Veldt AAM, et al. Critical evaluation of sentinel lymph node biopsy in pT1b and pT2a melanoma patients: A nationwide population-based study. Eur J Cancer. 2025. PMID: 40175255. doi:10.1016/j.ejca.2025.115365
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。